Between 20 and 30 percent of people with psoriasis eventually develop a second, more disabling problem: painful joint inflammation. Known as psoriatic arthritis, it can quietly worsen and, without ...

Knowing your psoriasis triggers can help you better manage your symptoms. Get psoriasis treatment strategies to improve your quality of life.

Incorporating patient-reported outcome measures, such as quality of life, as well as looking into real-world data, is ...

Two-year real-world data highlight strong drug survival and effectiveness of bimekizumab in plaque psoriasis. Learn more ...

Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in its effort to treat the incurable skin condition and ...

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

For people with psoriasis — a chronic skin disease in which skin cells build up, typically causing discolored, itchy or scaly patches — living with the condition itself is difficult enough. But on top ...

PARIS — A psoriasis treatment trial using a patient-centered outcome as the primary endpoint supports a World Health Organization (WHO) initiative to measure therapeutic benefit in chronic diseases ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

Major advancements in psoriasis treatments in the past two decades have given people living with the autoimmune condition a wide range of options for controlling symptoms. There are more than a dozen ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

Junshi Biosciences has announced that its IL-17 antibody hit the goals of a phase 3 psoriasis trial in China, setting up the biopharma to seek national approval. The Shanghai-headquartered company ...